Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.40 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2358740 | 0.86 | EPHX2 (0.43) | MEN1KMT2APOLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL2359845 | 0.84 | MEN1 (0.47) | LMNAMEN1KMT2APOLBTSHR | |
| SCHEMBL2359355 | 0.82 | FADS1 (0.43) | LMNAMEN1KMT2AALDH1A1TP53 | |
| SCHEMBL2361067 | 0.82 | LMNA (0.47) | LMNAMEN1KMT2APOLBSMN1; SMN2 | |
| SCHEMBL2360576 | 0.81 | LMNA (0.61) | LMNAMEN1KMT2APOLBSMN1; SMN2 | |
| SCHEMBL2359181 | 0.81 | KMT2A (0.43) | LMNAMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2358284 | 0.80 | KMT2A (0.51) | LMNAKMT2APOLBALDH1A1MAPT | |
| SCHEMBL2360096 | 0.80 | EPHX2 (0.34) | MEN1KMT2AEPHX2P2RX7 | |
| SCHEMBL2360156 | 0.80 | KMT2A (0.40) | MEN1KMT2APOLBSMN1; SMN2RAB9A | |
| SCHEMBL2360243 | 0.80 | EPHX1 (0.45) | LMNAMEN1KMT2APOLBSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011094953-A1 | COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-11 | — | — | WO | claimed |
| WO-2011095576-A1 | COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-11 | — | — | WO | disclosed |
| WO-2011094953-A1 | COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-11 | — | — | WO | disclosed |
| WO-2011094953-A1 | COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-11 | — | — | WO | disclosed |
| US-20110195979-A1 | COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-11 | — | — | US | disclosed |
| US-20110195979-A1 | COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195979-A1 | COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA | NAT1, NHERF1, ADORA1 | LMNA 1039/4885MEN1 1215/4885KMT2A 2790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.